Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Uman Pharma
With
dsm-firmenich Switzerland AG
MDEIE Ministry, Québec Government
INRS-Institut Armand Frappier , Université du Québec
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written Informed Consent.
Males or females.
18-75 years.
Histologically or cytologically confirmed non-estrogen dependent advanced solid malignancy who has failed standard therapies and/or for which no curative therapeutic option exists (phase I) or ;
Histologically or cytologically confirmed NSCLC of stage IIIb or IV (phase IIa) that has failed or is ineligible to standard therapies.
One or more tumor lesions measurable by RECIST criteria
Life expectancy of at least 3 months.
ECOG performance of 2 or less.
You may not be if
Prior decitabine or genistein therapy.
Received cytotoxic agent, hormonal therapy, radiation therapy, or other targeted cancer therapies or investigational agent within 4 weeks prior to study entry.
Patients with confirmed estrogen receptor-positive cancers, or patients with a primary breast or endometrial cancer for which phenotyping analysis has not been performed.
Presence of uncontrolled brain metastases or leptomeningeal disease.
Uncontrolled cardiovascular disorders, including symptomatic heart failure, unstable angina and cardiac arrhythmias.
Inadequate baseline organ function as shown by following laboratory values :
* Hemoglobin \< 90 g/L
* Absolute neutrophil count \< 1,500 /microliter
* Platelet count \< 100,000 /microliter
* Total bilirubin \> 1.5 ULN
* AST and ALT \> 2.5 ULN
* Creatinine clearance \< 60 ml/min
To be dependent of oxygen treatment.
Active infections requiring antibiotics.
Pregnancy or breastfeeding. All women of child-bearing potential must have a negative pregnancy test prior to first receiving protocol therapy.
Known allergic reactions to soy derivatives or deoxycytidine derivatives.
Active alcohol or drug abuse.
Any co-morbid condition that in the judgment of the investigator renders the subject at high risk of treatment complication or reduces the probability of assessing clinical effect.
Other malignancies diagnosed within the last 5 years with the exception of Basal Cell Carcinoma of the skin.
Gastrointestinal disorders or abnormalities that may interfere with the absorption of genistein.
Patients unable to comply with the study protocol and follow-up schedule for any psychological, familial, sociological or geographical reason.